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Original Article
Phase contrast mapping MRI
measurements of global cerebral
blood flow across different perfusion
states – A direct comparison with
15O-H2O positron emission tomography
using a hybrid PET/MR system
Oriol Puig1 , Mark B Vestergaard1, Ulrich Lindberg1,
Adam E Hansen1, Annette Ulrich2, Flemming L Andersen1,
Helle H Johannesen1, Egill Rostrup1, Ian Law1,
Henrik BW Larsson1 and Otto M Henriksen1
Abstract
Phase-contrast mapping (PCM) magnetic resonance imaging (MRI) provides easy-access non-invasive quantification of
global cerebral blood flow (gCBF) but its accuracy in altered perfusion states is not established. We aimed to compare
paired PCM MRI and 15O-H2O positron emission tomography (PET) measurements of gCBF in different perfusion states
in a single scanning session. Duplicate combined gCBF PCM-MRI and 15O-H2O PET measurements were performed in
the resting condition, during hyperventilation and after acetazolamide administration (post-ACZ) using a 3T hybrid PET/
MR system. A total of 62 paired gCBF measurements were acquired in 14 healthy young male volunteers. Average gCBF
in resting state measured by PCM-MRI and 15O-H2O PET were 58.5 10.7 and 38.6 5.7 mL/100 g/min, respectively,
during hyperventilation 33 8.6 and 24.7 5.8 mL/100 g/min, respectively, and post-ACZ 89.6 27.1 and
57.3 9.6 mL/100 g/min, respectively. On average, gCBF measured by PCM-MRI was 49% higher compared to
15O-H2O PET. A strong correlation between the two methods across all states was observed (R
2¼ 0.72, p< 0.001).
Bland–Altman analysis suggested a perfusion dependent relative bias resulting in higher relative difference at higher CBF
values. In conclusion, measurements of gCBF by PCM-MRI in healthy volunteers show a strong correlation with
15O-H2O PET, but are associated with a large and non-linear perfusion-dependent difference.
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Introduction
Quantitation of cerebral blood flow (CBF) is essential in
the study of brain pathologies and, even more, of brain
physiology. The generally accepted reference method for
CBF quantification in humans is 15O-H2O positron
emission tomography (PET),1 but it is technically chal-
lenging to perform as it requires both online production
of the radiotracer and arterial cannulation. The use of
15O-H2O PET is therefore limited to highly specialized
centers and selected clinical and research applications.
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Phase contrast mapping (PCM) magnetic resonance
imaging (MRI) allows fast, non-invasive, and reprodu-
cible measurements of blood flow in the arteries feeding
the brain.2 By normalizing the PCM measurements of
total blood flow (in mL/min) to brain weight, global
CBF (gCBF) can be calculated (in mL/100 g/min).
Due to its simplicity, PCM MRI measurements of
gCBF are increasingly being applied both in large
population studies3,4 and in quantitative studies of cere-
brovascular physiology.5 By combing PCM MRI with
susceptibility-based MRI oximetry, or similar MRI
techniques for the quantification of blood oxygenation,
global cerebral oxygen consumption can be quantified.6
Using such combined MRI approaches, a number of
articles have investigated the influence of aging7 and of
various acute interventions on cerebral oxygen metab-
olism.8,9 PCM MRI may also be used for the scaling of
relative MRI CBF measurements obtained by the
dynamic susceptibility contrast MRI10 or arterial spin
labelling (ASL) MRI.11,12
However, despite its popularity and widespread use,
validation studies of gCBF measurements by PCM
MRI with accepted reference methods are sparse. In
previous studies, PCM MRI measurements of gCBF
have proven to be in fair agreement with gCBF
values from the literature.3,13 An early study comparing
gCBF measurements obtained by 15O-H2O PET and
PCM MRI failed to find a significant correlation
between values obtained by the two techniques, but it
should be noted that the measurements were performed
months apart.14 A more recent study comparing same-
day PCM MRI and 15O-H2O PET measurements,
showed a strong positive correlation between gCBF
measurements in resting state, but demonstrated also
that PCMMRI yielded 63% higher gCBF values meas-
urements compared to 15O-H2O PET.
15 However, the
behavior of PCM measurements against an accepted
reference method in a broader range of CBF values,
e.g. during induced hypo- and hyperperfusion, has
not been established. Such knowledge is essential
when interpreting PCM MRI-dependent studies of
cerebral perfusion or oxygen metabolism during vari-
ous interventions.
A recent review highlighted the importance of the
time interval between CBF measurements in method
comparison studies by showing that the method agree-
ment increases when the measurements are performed
in close sequence.16 With the introduction of hybrid
PET/MRI scanners, simultaneous PET and MRI
CBF measurements can now be performed under iden-
tical physiological conditions eliminating important
sources of variability between the measurements in
acutely altered perfusion states, which may be difficult
to replicate when performing sequential imaging on
separate systems.
The aim of this study was to compare PCM MRI
against fully quantitative 15O-H2O PET measurements
of gCBF in resting state and in altered perfusion states
with a hybrid PET/MRI scanner. Furthermore, we uti-
lized the short 2min half-life to obtain multiple paired
observations by repetitive tracer injections as has been
done in piglets.17
Material and methods
Fourteen healthy young males (mean age 23.9 2
years, range 21 – 28 years) were enrolled in the study.
Inclusion criteria were: healthy males between 18 and
35 years old. Exclusion criteria were: contraindications
to MRI or arterial cannulation, a medical history of
prior or current neurological or psychiatric disease, or
severe head trauma. The rationale for studying only
males was to study a population as homogeneous as
possible and to benefit from the slightly larger vessel
diameter in males.
The study was approved by the Danish National
Committee of Health Research Ethics (H-16023156)
and was conducted according to the Declaration of
Helsinki II. Written informed consent was obtained
from all the participants.
Experiment setup
All PET and MR imaging were obtained on a 3T
Siemens Biograph mMR hybrid PET/MR system
(Siemens Healthcare, Erlangen, Germany) within a
single scanning session lasting approximately 2.5 h.
Volunteers were instructed not to consume coffee, tea,
chocolate or any other caffeine containing beverages 8 h
prior to the experiment because of the CBF modulating
effects.18 Before the scan, a light meal was offered to all
the participants.
Immediately before or after the PET/MRI scan, a
low radiation CT scan (120 kV, 30mAs, 5-mm slice
width) was performed in a PET/CT scanner (Siemens
Biograph, Siemens, Erlangen, Germany) and was used
for the attenuation correction of the PET images.19
An arterial catheter was placed in the radial artery
of the non-dominant hand to allow for arterial blood
sampling, and a venous line was placed in the median
cubital vein of the dominant forearm for the adminis-
tration of radiotracer and acetazolamide (ACZ). Foam
padding was placed around the head to minimize head
motion during the experiment and earplugs were used
to reduce the ambient noise.
Duplicate combined CBF PET/MRI measurements
were performed in resting condition, hypoperfusion and
hyperperfusion as shown in Figure 1. To induce hypo-
perfusion, volunteers were instructed to breathe deeply
at a respiratory rate of 24 respirations per minute.
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A metronome connected to the scanner’s sound system
was used to pace the respiration. The volunteers followed
the described hyperventilation for pattern 5min before
the measurements were performed to ensure the hypo-
perfusion state was achieved and stable. Hyperperfusion
was achieved by intravenous administration of ACZ (15-
20mg/kg, Diamox, Mercury Pharmaceuticals, London,
UK) over a 5-min period. Post-ACZ scans were com-
menced 20min after the end of ACZ administration.
Arterial blood samples were obtained at the end of
each PET CBF measurement. Arterial blood gases, pH,
and hemoglobin were analyzed in a Radiometer
ABL800 Flex system (Radiometer, Copenhagen,
Denmark). The arterial line was flushed with a heparin
solution (100 i.u./mL. Leo Pharma, Ballerup,
Denmark) after each scan to prevent clot formation.
Respiratory rate was monitored with a respiration
belt during the experiment, especially during the meas-
urements in hyperventilation, to ensure that the volun-
teer was following the hyperventilation scheme. Pulse
was monitored during the experiment using an MRI
compatible finger pulse oximeter connected to the scan-
ner for the pulse-triggered PCM MRI measurements.
Arterial blood pressure was measured prior to the
experiment, before and after the ACZ administration,
and at the end of the experiment.
MRI
A 16-channel mMR head and neck coil designed by the
vendor to minimize attenuation of the PET signal was
used for all the MRI measurements.
Structural imaging
A high-resolution structural scan was obtained prior to
the first CBF measurement using a 3D T1-weighted
magnetization prepared rapid acquisition gradient echo
(T1 MPRAGE) sequence (repetition time (time between
pulses, TR) 1900ms, echo time (TE) 2.44ms, flip angle
9 , matrix 256 256, voxel size 1.0 1.0 1.0mm3,
GRAPPA acceleration factor 2).
The anatomical scans were segmented using the FSL
BET and FAST tools20 in order to obtain a brain tissue
mask including cerebral hemispheres, cerebellum and
brain stem (and excluding the cerebrospinal fluid)
used for the calculation of the total brain volume and
to mask the PET CBF images. Brain weight was calcu-
lated assuming a brain tissue density of 1.05 g/mL.21
Flow measurements acquisition
A 3D time-of-flight (3D-TOF) angiogram (TR 22ms, TE
3.60ms, flip angle 18 degrees, matrix 256 232, FOV
200 181mm2 and voxel size 0.8 0.8 1.0mm3) was
performed prior to the PCM measurements in each state.
Pulse-triggered PCM measurements (single slice, TR
37.4ms, TE 3.32ms, flip angle 25 , FOV 320 240mm2,
voxel size 0.8 0.8 5.0mm3, 20 phases per cardiac
cycle and averaging 2 measurements, velocity encoding
(Venc) of 150 cm/s performed only in the direction
(superior-inferior) of the imaging plane) were com-
menced 7min after the beginning of the PET scan
(after other MRI perfusion measurements not included
in the present analysis). The duration of the scan was
approximately 2min, and varied slightly from subject-
to-subject depending on their heart rate. The 3D-TOF
angiograms maximum intensity projections were used
for the planning of PCM. A single PCM imaging
plane was placed at the level of the upper part of the
V2 segment of the vertebral arteries (VAs) and in the C1
segment of the internal carotid arteries (ICA), and angu-
lated as perpendicular as possible to the four arteries,
prioritizing optimal angulation of the ICAs (an example
is provided in Supplementary material, Figure S1).
MRI post-processing
PCM generated three dynamic images: a magnitude
image showing anatomy, a velocity image and a complex
subtraction image. All PCM images were converted to
NIfTI file format and processed using in-house software
for MATLAB version R2016b (TheMathworks, Natick,
MA, USA).
Figure 1. Experiment overview.
PCM: phase contrast mapping; ACZ: acetazolamide; TOF: time of flight arterial angiography; CBF: cerebral blood flow; *Other MRI
acquisitions.
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Average magnitude and velocity images were
created by averaging the signal over all phases of the
cardiac cycle. Regions of interest (ROIs) of the four
brain feeding arteries were initially manually drawn
on the average complex subtraction image and then
transferred to the averaged velocity maps. To avoid
the influence of vessel wall artefacts, voxels with an
average negative velocity in the periphery of the
vessel were excluded from the ROI. The ROIs were
then copied to the dynamic velocity maps and visually
inspected for aliasing and for voxels with erroneous
flow velocity patterns. Flow was calculated by multi-
plying the mean velocity with the cross-sectional area
of each ROI and then summation over 20 time-points
was performed.
PET
Acquisition
For each PET scan, a bolus of approximately 500MBq
of 15O-labelled water (15O-H2O) produced in an online
system (Automatic Water Injection System, Scansys
Laboratorieteknik, Værløse, Denmark) was manually
injected in the median cubital vein. Emission scans
were started at the time of the radiotracer injection
and recorded in list mode for 4min. At least 13min
passed between PET measurements to allow for the
tracer decay.
PET images were reconstructed into 18 5 s, 9 10 s,
4 15 s frames using 3D-ordered subset expectation
maximum (3D OSEM), 4 iterations 21 subsets,
128 128 matrix and 2mm Gaussian filter. The attenu-
ation correction was performed using m-maps generated
from the low-dose CT scan as previously described.19
Arterial blood sampling
Activity in the arterial blood was sampled at 1Hz during
the scans using an MR compatible automatic blood
sampling system (Swisstrace, Zu¨rich, Switzerland) set
to draw 8mL/min. Flow rate, material, length (50 cm)
and diameter (1mm) of the arterial line was identical to
our current clinical and research setup on our brain
dedicated PET scanner. The sampling system clock
was synchronized to the scanner acquisition clock for
the correct decay correction of the data. Blood sampling
was started approximately 90 s prior to the radiotracer
injection and was stopped 4min after the beginning of
the PET acquisition.
Post processing
Parametric images were generated with the software
PMOD 3.304 (PMOD Technologies, Zu¨rich,
Switzerland) using a one tissue two-compartment
model with correction for arterial blood volume fitting
the first 180 s from bolus arrival to the brain of the
dynamic sequence.22,23 The arterial input curves were
corrected for dead-time, decay, delay and dispersion.
CBF is reported as the unidirectional clearance of
tracer from the blood to the tissue (K1) assuming full
extraction of water. Each parametric CBF map was cor-
egistered to its corresponding anatomical T1-MPRAGE,
and the whole brain mask was applied to obtain gCBF
calculated as the average of all voxels within the mask.
Statistics
Summary results for each state are presented including
all the measurements. For reporting of summary stat-
istics (Tables 1 to 3), the results of the duplicate meas-
urements by each method were averaged in in each
state. Results of PCM MRI flow measurements from
both VAs and ICAs were also averaged. In all other
analyses and plots, all individual measurements in each
state were included.
For reporting of inter-state differences, only values from
subjects that completed combined measurements in two
states (post-ACZ and rest, and/or hyperventilation and
rest) were included. Inter-state differences were defined
as the difference between the individual non-resting
state measurement (post-ACZ or in hyperventilation)
and the average of the two resting state measurements.
Differences between states or modalities were investi-
gated using a Wilcoxon–Mann–Whitney test.
Method agreement was investigated by Bland–
Altman plots and by linear mixed analysis. In order
to take into account that multiple measurements were
performed in each subject, associations of PCM MRI
and 15O-H2O PET measurements of gCBF were inves-
tigated by a two-level linear mixed model with MRI
PCM gCBF as dependent variable, 15O-H2O PET
gCBF as fixed effect, and subject (m, level 2) as
random effects (and replicate measurement as residual,
e, level 1)
gCBFPCM ¼ 0 þ 1gCBFPET þ þ "
Identical models were analyzed for each state separ-
ately and for inter-state differences. Correlation coeffi-
cients (R2 values) for all states combined, and for each
state were calculated by comparing the sum of variance
components in similar two-level variance component
models with and without fixed effects.
In order to asses method precision, intra- and inter-
individual variability (coefficient of variation, CV) of
resting measurements was calculated as the standard
deviations of the random effects (m and e, respectively,
in a two-level linear mixed model similar to that above
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Table 3. Averaged global cerebral blood flow assessed by 15O-H2O PET and phase-contrast mapping MRI.
Resting
(n¼ 26/14)
Hyperventilation
(n¼ 17/9)
Post-acetazolamide
(n¼ 19/10)
PCM MRI (mL/100 g/min) 58.5 10.7b (0.18) 33.0 8.6a,b (0.26) 89.6 27.1a,b (0.30)
Change vs. rest (mL/100 g/min) – 26.9 9.5 31.3 17.9
Change vs. rest (%) – 36.9 19.6 52.4 23.8
15O-H2O PET (mL/100 g/min) 38.6 5.7b (0.15) 24.7 5.8a,b (0.23) 57.3 9.6a,b (0.17)
Change vs. rest (mL/100 g/min) – 16.4 10.5 19.4 8.3
Change vs. rest (%) – 35.0 10.2 52.5 22.6
Note: All values are the average standard deviation of the two measurements in each condition, coefficient of variation in parenthesis. For each state,
n indicates the number of observations /number of subjects. The change is calculated as the difference of the average gCBF in resting state and in
hyperventilation or after acetazolamide. Only subjects with measurements in at least two states contribute the calculation of gCBF changes.
ap< 0.05 for differences with resting state, within technique.
bp< 0.05 for differences between techniques, within state.
PCM MRI: phase contrast mapping magnetic resonance imaging; PET: positron emission tomography; gCBF: global cerebral blood flow.
Table 1. Cardiorespiratory variables during the experiment.
Resting
(n¼ 26/14)
Hyperventilation
(n¼ 17/9)
Post-acetazolamide
(n¼ 19/10)
Heart rate (min1) 59.4 8.3 66.8 9.4a 64.4 10.9
Respiratory rate (min1) 16.4 2.0 24.2 0.4a 17.6 1.8
pH 7.40 0.01 7.54 0.07a 7.39 0.03
PaCO2 (kPa) 5.8 0.4 3.7 0.8a 5.5 0.3a
PaO2 (kPa) 13.8 0.9 16.8 1.6a 14.0 1.0
ctHB (mmol/L) 9.6 0.7 9.4 0.4 9.3 0.4
SaO2 (%) 97.8 0.4 99 0.4 97.7 0.4
Note: Values are the average standard deviations of the two measurements in each condition. For each state, n
indicates the number of observations/number of subjects.
ap< 0.005 for difference versus resting conditions.
PaCO2: arterial pressure of CO2; PaO2: arterial pressure of O2; ctHB: concentration of hemoglobin; SaO2: arterial
saturation of O2.
Table 2. Characteristics of phase-contrast mapping MRI measurements per vessel.
Rest
(n¼ 26/14)
Hyperventilation
(n¼ 17/9)
Post-acetazolamide
(n¼ 19/10)
ICA VA ICA VA ICA VA
Vmax (cm/s) 55.1 9.3 30.6 7.7 45.4 9.1a 27.4 11.1a 60.9 11.9a 33.8 9.5a
Flow (mL/min) 285.4 58.3 92.0 42.3 171.0 46.2a 48.0 32.5a 428.3 121.3a 139.4 82.7a
Contribution to gCBF (%) 38.0 4.3 12.0 4.9 39.5 4.6 10.5 5.5 37.9 4.1 12.1 5.5
Total flow (mL/min) 755 146 435 124 a 1124 341a
Note: Values are the average standard deviation of the left and right arteries in each condition. For each state, n indicates the number of obser-
vations/number of subjects.
ap< 0.005 for differences versus resting conditions (within artery).
ICA: internal carotid arteries; VA: vertebral arteries; Vmax: voxel peak velocity; gCBF: global cerebral blood flow.
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with either gCBFPET or gCBFPCM as outcome and
including only measurement number as fixed effect)
divided by the population mean.
Results
Nine of the fourteen volunteers had measurements per-
formed in all three states. In one volunteer, measure-
ments during hyperventilation were omitted due to the
time restrictions. In the remaining volunteers that did
not complete the scanning protocol, this was prema-
turely terminated due to the clotting of the arterial
line (n¼ 3), or at the request of the volunteer (n¼ 1).
In total, 62 paired observations were performed by
PET/MRI: 26 measurements in resting state in 14 vol-
unteers, 17 measurements during hyperventilation in 9
volunteers, and 19 measurements after administration
of ACZ in 10 volunteers. Two combined measurements
were discarded due to the suboptimal data quality of
PCMMRI measurements as a consequence of excessive
head movement at the end of the experiment.
Physiological measurements in the three different
states are shown in Table 1. During hyperventilation,
there was a reduction of 0.6 kPa in the average PaCO2
in the second measurement compared to the first one
(p< 0.005). Hyperventilation significantly decreased
PaCO2 and increased heart rate, pH and PaO2. After
the administration of ACZ, a small, but significant
decrease in PaO2 was observed along with a slight,
but non-significant, increase in the respiratory rate.
The average brain tissue volume was 1347 77mL.
The results of the PCM MRI measurements for each
vessel in the three different states are shown in Table 2.
No aliasing was observed in any of the PCM MRI
measurements. The range of fitted delay and dispersion
values of the 15O-H2O input function was 9–15 s and 5–
6 s, respectively, corresponding to what we obtain using
the same arterial line and kinetic models in healthy men
scanned in a dedicated brain PET HRRT scanner.
Examples of CBF measured by 15O-H2O PET and
PCM MRI in each state are shown in Figure 2
Values of gCBF assessed by PCM MRI and
15O-H2O PET in the three different states are summar-
ized in Table 3. Overall, a highly significant positive
correlation of PCM MRI with 15O-H2O PET across
all states was observed. Within each state, the correl-
ation between methods was generally weaker, but
statistically significant for rest and post-ACZ states
(Figure 3(a) and Table 4).
PCM MRI yielded higher gCBF values compared to
15O-H2O PET: 47.7% on average across all states, and
35.9%, 51.5% and 53.7% on average during hyperven-
tilation, in rest and after ACZ, respectively. Figure 3(a)
demonstrates a relative, perfusion-dependent increase
in the difference between the PCM MRI and the 15O-
H2O PET gCBF values. This is confirmed by the
Bland–Altman plot (Figure 3(b)) also showing that
the relative difference increases with increasing perfu-
sion. The positive slope corresponds to a 0.7%-point
increase in the relative difference between PCM MRI
and 15O-H2O PET per mL/100 g/min increase in the
average of the two techniques, i.e. 26% at an average
of 20mL/100 g/min and 69% at 80mL/100 g/min. The
estimate of the regression coefficient in each state
tended to be lower than the overall estimate (Table
4). Scatter plots of gCBF measured by PCM MRI
and by 15O-H2O PET for each individual state can be
found in the Supplementary Material (Figure S2).
The agreement of PCMMRI with 15O-H2O PET for
the quantification of absolute gCBF changes from base-
line to hyperventilation and after ACZ was in general
poorer, with weak correlation and borderline signifi-
cance (Table 4 and Figure S3).
Intrasubject variability (CV) of gCBF in resting state
was 6.2% for PCM MRI and 6.4% for 15O-H2O PET.
The corresponding CVs of intersubject variability were
17.0% and 13.6%, respectively.
Discussion
The present study is unique by obtaining multiple com-
bined PCM MRI and fully quantitative 15O-H2O PET
gCBF measurements with arterial blood sampling in
healthy volunteers across different perfusion states in
a single imaging session using a hybrid PET/MRI
system. The most important contribution of single
scan session PET and MRI (near-) simultaneous ima-
ging is achieving the best possible matching of physio-
logical parameters known to influence CBF, e.g.
arterial blood gasses, pH, hemoglobin, caffeine levels,
and sensitivity to ACZ,17,24 that will be challenging to
match in a dual scan session set-up.25 The study shows
a strong correlation between the PCM MRI and
15O-H2O PET gCBF over a wide range of perfusion
values confirming the capability of PCM MRI to pro-
vide quantitative gCBF measurements, also at lowered
and increased perfusion. However, we also found a
perfusion-dependent increasing relative difference with
PCM MRI yielding higher gCBF values compared to
15O-H2O PET, and relatively poor agreement with
regard to quantitation of gCBF changes. The study
demonstrates the potential of hybrid PET/MRI scan-
ners to perform intra-session physiological measure-
ments independently, and importantly also that it is
possible to perform such measurements involving a
complex setup despite the physical limitations of the
experimental environment.
The average gCBF in resting state measured by
PCM MRI (58.5 10.1mL/100 g/min) and by
15O-H2O PET (38.6 5.71mL/100 g/min) is over- and
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underestimated, respectively, compared to the generally
accepted text book value for resting gCBF around
46–50mL/100 g/min.26,27 They are, however, in good
agreement with those reported previously by other
authors using identical methods,13,28 confirming the
correct implementation of the measurement techniques.
The absolute gCBF increase after the administration of
ACZ measured by PCM MRI and by 15O-H2O PET is
also in good agreement with published studies.28,29
The study confirms the previous finding of a large
and systematic relative difference in the order of 50%
between PCM MRI and 15O-H2O PET reported by
Vestergaard et al.15 In our study, the correlation
between methods in resting state was lower than that
reported by Vestergaard et al. (R2¼ 0.17 vs. 0.44).15
The lower correlation coefficient could to some extent
reflect random variation due to the lower number of
independent measurements in the present study. The
intrasubject variability of approximately 6% for both
techniques, however, is very similar to that reported by
Vestergaard et al (6.5% for PCM MRI and 5.7% for
15O-H2O PET) and does not suggest increased method
imprecision as a cause of the observed lower correl-
ation. The slope of the linear fit in the study of
Figure 2. Examples CBF measurements. Panels show 15O-H2O PET CBF images (top row), PCM MRI average velocity images across
the cardiac cycle (middle row) and arterial mean velocity of each vessel over the cardiac cycle (bottom row) in each state from a single
volunteer. Colored ROI for each vessel are displayed over the average velocity images and the corresponding arterial flow over the
cardiac cycle is shown below. L: left; R: right.
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Vestergaard et al. is somewhat steeper, but well within
the confidence interval of the estimate of the rest meas-
urements in the present study (1.32 vs. 0.89 [CI: 0.28–
1.50]). We therefore conclude that the findings of the
present study are not in conflict with the previous study
from Vestergaard et al.
The basis of the PCM MRI and 15O-H2O PET
gCBF difference has been discussed in details
previously15 and can, in large, be attributed to system-
atic overestimation of flow measured by PCM MRI
and underestimation by 15O-H2O PET.
For PCM MRI, partial volume effects may lead to
an overestimation of the measured flow in particular if
the vessel diameter is low compared to image resolution
or when measurements are not performed perpendicu-
lar to the vessel.30,31 We used a single imaging plane to
measure the arterial flow in all four arteries, which
might lead to a sub-optimal positioning of the plane
for the measurements of some of the vessels. For this
reason, we prioritized correct positioning of the ima-
ging plane of the ICAs contributing to almost 80% of
the total cerebral flow. We also found that the flow
distribution between ICAs and VAs is constant across
perfusion states which support linearity between the
measured flow and true flow.
Underestimation of the 15O-H2O PET gCBF measure-
ments may largely be explained by the limited water extrac-
tion fraction across the blood–brain barrier (approximately
0.85 at resting CBF values) when quantifying CBF
from 15O-H2O PET using the unidirectional clearance
rate constant, K1, of a one-tissue two-compartment
model.32 The diffusion limitation has the most pro-
nounced effect at high CBF values, which probably
explains the observed perfusion-dependent difference
values of PCM MRI compared to 15O-H2O PET.
Figure 3. Correlation of gCBF measurements by 15O-H2O PET and PCM MRI. (a) Scatter plot of global cerebral blood flow (gCBF)
measured by 15O-H2O PET and phase-contrast mapping (PCM) MRI during hyperventilation (red), in rest (blue) and after acetazo-
lamide (green). (b) Bland–Altman plot showing the ratio of the two methods against mean of the methods. Yellow line shows the linear
fit from the mixed model. In 3(a), grey line indicates the line of identity. In 3(b), solid grey and dashed lines indicate bias upper and
lower limits of agreement (bias 2 SD), respectively.
Table 4. Association of global cerebral blood flow measure-
ments by 15O-H2O PET and PCM MRI.
Estimate (95% CI) p R2
All states 1.69 (1.55; 1.82) <0.001 0.72
Rest 0.89 (0.28; 1.50) 0.008 0.17
Hyperventilation 0.87 (0.06; 1.81) 0.063 0.33
Change from rest 0.46 (0.03; 0.95) 0.061 0.08
Rel. change from rest 0.47 (0.26; 0.68) <0.001 0.33
Post-acetazolamide 1.30 (0.38; 2.22) 0.011 0.33
Change from rest 1.02 (0.07; 2.12) 0.064 0.07
Rel. change from rest 0.61 (0.18; 1.42) 0.11 <0.001
Note: Estimate represents regression coefficient in the two-level mixed
model. Changes are calculated as absolute and relative change from aver-
age of the two resting measurements to each subsequent measurement.
CI: confidence interval; PCM MRI: phase contrast mapping magnetic res-
onance imaging; PET: positron emission tomography.
8 Journal of Cerebral Blood Flow & Metabolism
For this study, a fixed Venc of 150 cm/s was used in
all measurements in order to maintain the scanning
protocol throughout the different measurements
and to prevent aliasing in high flow measurements.
Our results show a mean peak voxel velocity of
60.9 11.9 cm/s in the ICAs after the administration
of ACZ, and the highest voxel peak velocity measured
was 87 cm/s. The use of a Venc of 150 cm/s seems to be
excessive for this experiment,33 a Venc of approximately
100 cm/s would be reasonable when scanning healthy
young volunteers in different perfusion states.
It is noteworthy that the slope (the regression coef-
ficient estimate) in rest differs from the overall slope
and the confidence intervals do not overlap. However,
it should also be noted that the estimates in each of the
three states are overlapping and tend to be lower than
the overall estimate and not significantly different from
one. In a post hoc analysis, applying three-level random
effects model with interaction term failed to demon-
strate significant state-dependent differences. We inter-
pret this as the overall slope mainly reflects the general
approx. 50% difference between methods and that a
common intercept is forced upon data when applying
a single linear fit. Analyzing each state separately
allows a better fit of data with state specific intercepts
and a slope closer to optimal value of one in each state.
The slightly lower than one slope in rest and hyperven-
tilation could be the consequence of statistical attenu-
ation bias due to method imprecision of the PET
measurements, whereas the steeper slope in post-ACZ
measurements can be attributed to the limited water
extraction at higher perfusion values.
The present study has some limitations. First of all,
MRI and PET data were acquired in close sequence,
but not completely simultaneously. However, the time
span was less than 10min and there were no significant
differences between the repeated gCBF PET measure-
ments within each state, indicating physiologic stability.
Another limitation is the limited number of subjects
studied and the relatively high number of incomplete
studies as a consequence of the complexity of the setup.
Although the study population was relatively small, it is
compensated by multiple paired measurements in dif-
ferent perfusion states using repeated tracer injection.
This means that the number of paired measurements
exceeds the number obtained in the largest previously
published study comparing of CBF measurement using
PCM MRI and 15O-H2O PET (performed in two sep-
arate sessions) by a factor of 3.15 It was therefore con-
cluded that the overall findings were robust and would
not have changed by increasing number of subjects.
The relatively high proportion of incomplete studies
due to arterial line clotting in 3/14 sessions was possibly
related to the suboptimal wrist position due to the
physical constrains at the edge of the bore opening.
This supports the perception that quantitative
15O-H2O PET is a technically challenging procedure
to perform. For these reasons, it would be convenient
to have an alternative technique to simplify or substi-
tute it. In the same way as PCM MRI measurements
may be used to scale relative perfusion maps by ASL,11
PCMMRI could also be used to scale relative 15O-H2O
PET perfusion maps, thereby replacing arterial blood
sampling. Doing so would potentially overcome the
errors related to limited water extraction and this
approach has been studied in piglets.17 It should be
noted though, that the actual flow values obtained by
PCM MRI are highly dependent on in-plane reso-
lution30,31 and may even vary between sites although
using identical MR systems and acquisition param-
eters13 meaning that there is still no generally accepted
standard acquisition protocol for PCM MRI.
The poorer correlation of absolute gCBF changes at
the single subject level compared to the study popula-
tion level is most likely due to method-imprecision and
bias from both the methods in both states. Analyzing
relative changes, the correlation of hyperventilation-
induced hypoperfusion was greatly improved, but the
correlation of gCBF changes after ACZ, however,
remained poor. This is most likely related to the
decreasing water extraction fraction in the hyperperfu-
sion state. The weak correlation between the techniques
for quantification of between-states gCBF changes sug-
gests that PCM MRI and 15O-H2O PET measurement
of gCBF changes cannot be used interchangeably at the
single subject level due to their different behavior at
high perfusion states. It has to be noted, however,
that despite its limitations, gCBF changes assessed by
15O-H2O PET have been extensively validated clinically
and in physiological experiments.28,34 Further investi-
gations are required if PCM-scaled relative CBF maps
are to be applied for clinical assessment of regional flow
reserve.
Additionally, any systematic perfusion-dependent
biases in gCBF PCM MRI measurements will propa-
gate into any calculation of derived physiological meas-
urements such as CMRO2.
6 The particular relationship
between 15O-H2O PET and PCM gCBF measurements
needs to be acknowledged when replacing 15O-H2O
PET with PCM MRI in quantitative studies of brain
physiology. The observed non-linear bias can largely be
explained by the method-related bias as discussed
above, and PCM MRI may provide a more linear cor-
relation with true CBF at high flow values than
15O-H2O, although the latter cannot be determined
from the presents study.
In conclusion, this study shows that PCM MRI and
15O-H2O PET gCBF measurements performed in close
sequence across different perfusion states are highly
correlated, which confirms the ability of PCM MRI
Puig et al. 9
to perform gCBF measurements. The data, however,
also confirmed considerable and perfusion-dependent
relative bias between the two techniques. Finally, this
study demonstrates the potential of hybrid PET/MRI
systems to perform multiple paired intra-session quan-
titative physiological measurements independently,
which is crucial for MRI validation studies when
using PET as reference.
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